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Introduction: Osteoarthritis (OA) is the most common chronic degenerative joint 
disease that leads to damage and disability of the joints. Several studies mentioned the 
association between inflammatory process and clinical changes. However, there is no drug 
approved yet to cure the disease and to regenerate the tissues. Lysyl Oxidase-Like-2 
(LOXL2) could be a potential candidate as shown in our previous studies. We showed that 
LOXL2 is elevated during fracture healing and critical regulator of chondrogenesis. 
Recently, we showed that LOXL2 is shown to be anabolic to human OA cartilage. The 
goal of this study is to determine the protective effect of LOXL2 in temporomandibular 
(TMJ) and knee joint OA and to evaluate if LOXL2 attenuates the adverse effects induced 
by IL-1β in chondrocytes and osteoblasts. 
 
Materials and methods: To evaluate the anti-catabolic effect of LOXL2 in vitro, 
ATDC5 and MC3T3 cells have been transduced with Adv-RFP-LOXL2 and treated with 
IL-1β. The protective effect of LOXL2 in vivo was evaluated by systemic injection of 
adenovirus LOXL2 in a chondrodysplasia mouse model (Cho/+) and intra-articular MIA 
 
 vi 
injection in LOXL2 in transgenic mice followed by an analysis of TMJ and knee joints 
structural and functional analysis. 
 
Results: LOXL2 protects from adverse effects induced by IL-1β in ATDC5 and 
MC3T3 cells by inhibiting the phospho-NF-κB signaling pathway independent of LOXL2 
enzymatic activity. Also, LOXL2 increased the mRNA expression of Aggrecan and SOX9 
and decreased the level of ADAMTS5, MMP13 and RANKL induced by IL-1β. LOXL2 
promotes the mRNA level of ACAN and SOX9 in Cho/+ in TMJ and knee joints. 
Moreover, IHC analysis showed that ACAN expression is increased and MMP13 
decreased in TMJ and knee tissues. LOXL2 overexpressed mice injected with MIA covered 
more distances and spent more time on the treadmill than wild-type littermates in a 
treadmill test. IHC analysis showed more ACAN and less MMP13 staining in the LOXL2 
overexpressed group than the control one. 
 
Conclusion: LOXL2 was shown to attenuate adverse effects induced by IL-1β in 
chondrocytes and osteoblasts. LOXL2 has a protective and anabolic role in TMJ and knee 
joints affected by OA. Further, LOXL2 was shown to have a protective function during 
OA-related disability. 
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Osteoarthritis (OA) is the most common degenerative joint disease that leads to damage and 
joint disability. It is progressive and irreversible destruction of the joints, which is driven by 
defective cartilage extracellular matrix (ECM) remodeling and the loss of chondrocytes due to 
apoptosis (Zamli and Sharif, 2011). Knee pain and symptomatic knee OA have increased in 
prevalence (Larrea et al., 1990), and similar manifestations of the disease process are seen in 
temporomandibular joint (TMJ) disorders (Scrivani et al., 2008). Advances in understanding the 
disease pathogenesis are critical to OA prevention and treatment. Although cartilage destruction 
is a central feature in OA, pain and disability results from processes that affect multiple tissues 
that contribute to joint structure and function including the subchondral bone tissues, synovium, 
meniscus and the periarticular muscles, whole joint disease (Figure 1 and 2) (Xia et al., 2014). In 
the United States, the prevalence of OA is around 10% and the estimated lifetime risk of knee OA 
is 14% (Losina et al., 2013) with annual healthcare costs exceeding $185 billion in the United 
States (Wang et al., 2014).  
It is a multifactorial disease, but mechanical factors play a major role in the process of 
functional and the structural damage of the joints (Martin and Buckwalter, 2001). Some genetic 
predisposition can affect the incidence of the disease such as age, obesity, and joint mal-alignment. 
It was shown that loss of intact meniscus will lead to OA because of the mechanical forces and the 
joint instability (Xia et al., 2014). Catabolic and anabolic activities balance is important for 





will impair the homeostasis of the joint and eventually leads to cartilage loss (Mueller and Tuan, 
2008).  
 
1.2. TMJ and knee joints: 
Major components of the articular cartilage are tissue fluids, collagen, and proteoglycans. 
Chondrocytes are responsible for maintaining the cartilage by synthesizing important matrix 
components and degrading enzymes to maintain the homeostasis status. 
The cross-linked collagen network and mature cartilage can absorb and protect the joint from 
mechanical stress (Xia et al., 2014).  
TMJ is a synovial joint which controls jaw movement and consists of the mandibular fossa 
of the temporal bone and the condyle (Figure 2).  The articular disc of the joint comprises a hard-
dense fibrous connective tissue with containing collagen fibers bilaterally between the fossa and 
the mandibular condyle (Dijkgraaf et al., 1996b). On the other hand, the knee joint is a large hinge 
synovial joint and consists of bone, meniscus, ligaments and tendons (Dijkgraaf et al., 1996a). The 
degenerative cartilage processes develops similarly in both knee and TMJ. The major difference 
between knee and TMJ is the cartilage type that forms the articular lining (Holmlund et al., 1991). 
In knee joints, the articular surface is covered with hyaline cartilage, while in the TMJ, this lining 
consists of fibrocartilage. Also, the lining cartilage of TMJ is mainly composed of collagen type I, 









Figure 1. Differences of normal and OA affected knee joint structure: in OA, the affected 
joint shows imbalanced bone remodeling, cartilage destruction and meniscal damage with 
synovial hypertrophy. OA is a whole joint disease and it affects all structures included in the 






Figure 2. Differences of normal and OA affected TMJ joint structure : TMJ is a 
fibrocartilage joint with articular disc in between upper and lower joint cavities. The joint is 
mainly consists of mandibular condyle resting in the mandibular fossa of the maxilla. In this 
image the OA affected joint appeared with destroyed cartilage and damged surrounding 





1.3. Pathogenesis of osteoarthritis: 
Molecular factors, including growth factors, inflammatory cytokines, and reactive oxygen 
species (ROS) play a role in the OA process (Loeser, 2006).  Several clinical studies mentioned 
that there is an association between the inflammatory process and clinical changes. Although this 
inflammatory role in OA has been studied extensively, the exact mechanism and system that leads 
to matrix degradation and cell death are unknown (Figure 3) (Pelletier et al., 2001). Pro-
inflammatory cytokines such as tumor necrosis factor TNF-α and interleukin IL-1β are catabolic 
cytokines involved in chondrocyte apoptosis and matrix proteolysis; they contribute to the 
pathophysiology of OA (Wojdasiewicz et al., 2014). IL-1β is one of the most common pro-
inflammatory cytokines in the OA pathogenesis (Figure 4). Anabolic factors that have roles in 
chondrogenesis and articular cartilage maintenance have been used as additive factors in tissue 
engineering strategies and considered as candidate structure-modifying agents for OA therapy. So, 
alternative approaches to regulate these inflammatory cytokines could lead to improved therapies 
(Strowig et al., 2012).  
 
1.4. Clinical manifestations of Osteoarthritis: 
Pain is one of the most common symptoms that leads the patient to seek hospital care 
(Hadler, 1992), in addition to other symptoms such as joint swelling, stiffness, and crepitus. The 
common tool to diagnose OA is clinical exam,confirmed with different types of radiographs. 
OA management is a combination of different treatment modalities depending on the case 
severity and the symptoms to be relieved (Hunter and Felson, 2006), However, there is no 





tissues, but just to relieve the symptoms (Chockalingam et al., 2011). The recommended 
treatment strategy should start with non-pharmacological treatment then drugs, followed by 
surgery if needed in late-stage OA. The non-pharmacological approach consists of exercise, 
education, weight loss and sometimes relieving of joint stress causing the disease. The 
pharmacological approach should be started with analgesics before proceeding with the common 
used drugs such as NSAID and opioids. All of the used intra-articular drugs are for reliving the 
symptoms but not to cure or regenerate the joint. Last treatment option but unfavorable one is 
the surgery such as osteotomy or the joint replacement, usually applied in late-stage OA (Hunter 
and Felson, 2006).  
Preclinical studies in animal models have highlighted the potential efficacy of new agents for OA 
therapy (Chockalingam et al., 2011). New treatment modalities have been applied recently, such 
as anti-cytokine therapy and administration of growth factors, stem-cell therapy, and lubricant 
agents, such as lubricin.  Intra-articular hyaluronic acid (HA) therapy in OA is widely used 
worldwide because of the reported improved cases in both functional activity and pain 
management. HA is a matrix cartilage component which plays a major role in the joint 
homeostasis. HA is also secreted by chondrocytes which protect the cartilage from being degraded 







Figure 3. Factors affecting OA: although the disease is multifactorial, mechanical injury is the 
main factor affecting OA initiation. Some other factors will increase the severity of OA and 






Figure 4. Different types of cells could contribute to the pathology of OA joints: As OA is a 






1.5. Lysyl Oxidase Like-2 (LOXL2): 
LOX family members are (LOX, LOXL1-4) which are copper-dependent amine oxidases 
that function in ECM remodeling and collagen cross-linking (Makris et al., 2014). All members 
have conserved C-terminal domains which provide the activity for all lysyl oxidases. Although all 
members share a conserved catalytic C-terminal region, LOX and LOXL1 are much more closely 
related to each other than to LOXL2 – LOXL4. LOX has an important role in bone development 
but unknown role in regulation and bone formation. A previous study showed that LOXL2 is 
highly expressed in fracture healing areas in mice during the chondrogenic phase, which promotes 
chondrogenesis and the formation of cartilage ECM. LOXL2 also has an important role in vitro in 
ATDC5 chondrocyte differentiation by controlling important differentiation transcription factors 
such as SOX9 and Snail (Iftikhar et al., 2011).  
Previous studies showed that LOXL2 is highly expressed during fracture healing in mice and that 
it promotes chondrogenesis and the formation of cartilage ECM (Iftikhar et al., 2011). 
Furthermore, exogenous LOXL2 up regulates anabolic gene expression (COL2A1, SOX9, 
ACAN). In addition to that, LOXL2 showed for the first time its anabolic effect to human OA 
cartilage and induced a chondroprotective response. Microarray analysis demonstrated that 
transduction of HAC-OA with Adv-LOXL2 increases the expression of anabolic genes, including 
ACAN and SOX9. Also, LOXL2 was found to be anabolic effector that attenuates phospho-NF-
κB-p65 signaling pathway induced by IL-1β in human articular chondrocyte (Figure 5) (Alshenibr 



















Figure 5. Microarray analysis after LOXL2 overexpression in primary human articular 
chondrocytes (HAC): Human articular chondrocytes (HAC)-OA from three different OA 
patients were grown in chondrocyte growth medium (Lonza) and infected with adenovirus 
(Adv)-Empty (control) or Adv-LOXL2 (ADV-LOXL2) at MOI of 25. Next day, the cultures 
were replenished with serum-free medium and incubated for 24 h. Total RNA was subjected to 





1.6. Human TMJ chondrocyte implantation in nude mice: 
Freshly isolated human TMJ-OA condylar cartilage explants in 4-mm cubes were 
surgically implanted subcutaneously in the backs of nude mice (3 implants/mouse). Human 
cartilage 4mm3 cartilage implants were combined with  a specialized matrix (Geltrex™; 
ThermoFisher Scientific, Inc) as a basement membrane. The studies showed that Geltrex™ helps 
to maintain pluripotent stem cells and does not adversely affect chondrogenic differentiation 
(Mansson-Broberg et al., 2016). Geltrex™, basement membrane matrix and adenovirus 
combination is used in in-vivo studies related endochondral ossification of porcine cartilage repair. 
As per the manufacturer, Geltrex™ matrix includes laminin, collagen IV, entactin, and heparin 
sulfate proteoglycans lactose dehydrogenase-elevating virus (LDEV) - free and reduced growth 
factor basement membrane matrix. It is ideal for the promotion and maintenance of differentiated 
phenotypes in a variety of cell cultures, including primary epithelial cells, endothelial cells, smooth 
muscle cells, and human induced pluripotent stem cells (Klinger et al., 2011).  
 
1.7.Chondrodysplasia (Cho/+) mouse model:  
The Cho/+ mice were generated originally from Dr. Yefu Li, Harvard Medical School and 
bred with C57/BL6 to maintain heterozygous mice colony and genotyped by PCR as a standard 
protocol. Chondrodysplasia (Cho/+) mice are a reliable model to evaluate the role of LOXL2 in 
the progressive catabolic process occurring in OA. These mice are haplo-insufficient for a single-
nucleotide deletion that results in premature termination of the COL11A1 gene encoding the α1 
chain of type XI collagen (Li et al., 1995). This leads to progressive knee-OA starting at age 3 





et al., 2003) (Salazar et al., 2014). Data from human and animal experiments showed that decreased 
amounts of type XI collagen in cartilage might be one of the initiating factors in the pathogenesis 
of TMJ-OA (Salazar et al., 2014) and knee-OA (Xu et al., 2003). 
 
1.8.Constitutive overexpression of LOXL2 in transgenic mice: 
Mice with a targeted Loxl2 transgene (loxP-PGK-neo-stop-loxP-LOXL2-IRES-eGFP) 
were crossed to ROSA26-Cre to express LOXL2 constitutively (Martin et al., 2015). To evaluate 
if constitutive overexpression of LOXL2 in mice protects from OA pain and inflammation, 
Monosodium Iodoacetate (MIA) injected in the left knee (n=12/condition) of 13-month-old (aged) 



























2. Hypothesis and Aims: 
 
2.1. Hypothesis: 
We hypothesize that LOXL2 has a protective function on TMJ and Knee joints affected by 
osteoarthritis. Moreover, LOXL2 attenuates the adverse effects of IL-1β in OA. 
 
2.2. Aims: 
Aim1: Determine the protective effect of LOXL2 in vitro and evaluate how LOXL2 
attenuates adverse effects induced by IL1-β in OA on: 
a- Chondrocytes.  
b- Osteoblasts 
Aim2: Determine if LOXL2 gain of function protects TMJ and knee joint from developing 
OA in vivo: 
a- Human TMJ and knee OA cartilage implant in nude mice. 
b- Chondrodysplasia (Cho/+) OA mouse model. 
















3. Materials and methods: 
 
3.1. Preparation of adenovirus: 
Adenoviruses for transient expression of LOXL2 (Ad- CMV-RFP-CMV-hLOXL2-His; 
referred to as Ad-RFPLOXL2), and its empty vector (EV) control (Ad-RFP-EV) were custom-
synthesized (ADV-214438) by Vector Biolabs. These adenovirus particles were amplified in 
293 T cells and quantified using an adenovirus quantification kit (Cell Biolabs). The expression 
of LOXL2 protein was evaluated by western blotting of the medium and cell layer, and 
enzymatic activity (Palamakumbura and Trackman, 2002) of purified LOXL2 was evaluated by 
the Amplex Red assay. 
.  
3.2. ATDC5 cell line: 
ATDC5  is a cell line derived from mouse teratocarcinoma cells and characterized as a 
chondrogenic cell line; it provides a good model system for chondrocyte differentiation (Atsumi 
et al., 1990). 
 
3.3. Adv-RFP-LOXL2 transduction and IL-1β treatment in ATDC5 cells for gene 
analysis: 
To investigate the anti-catabolic effect of LOXL2 on chondrocytes, 250,000 ATDC5  cells 
were plated in each well of 6-well plates and 1µl/ml of Adv-RFP-LOXL2 or Adv-RFP-Empty was 





IL-1β in 10% serum differentiation media (readymade from Cell Application, Inc), then collected 
in two-time points (day 1 and 3) for mRNA analysis of different genes. 
3.4. MC3T3 cell line: 
MC3T3 cells, established as an osteoblastic cell line from normal newborn mouse 
calvaria, was selected upon the high activity of Alkaline Phosphatase (ALP) in the confluent 
state. It is widely used as a model system in bone biology studies by exhibiting a typical 
osteoblastic morphology (Sudo et al., 1983). 
 
3.5. Adv-RFP-LOXL2 transduction and IL-1β treatment in MC3T3 cells for gene 
analysis: 
To evaluate the anti-catabolic effect of LOXL2 in osteoblasts, besides its effect on 
chondrocytes; 250,000 MC3T3 cells were plated in each well of 6 well plates and 1µl/ml of Adv-
RFP-LOXL2 and Adv-RFP-Empty was transduced in the next day. After 24h, cells were washed 
with  sterile PBS and treated with 10 ng/ml IL-1β in 10% serum differentiation media (α-MEM 
supplemented with 10 nM dexamethasone, 25 µg ascorbic acid and 10 mM β-glycerophosphate), 
then collected at two-time points (24 and 48h) for mRNA analysis of different genes. 
 
3.6. Adv-RFP-LOXL2 transduction and IL-1β treatment in ATDC5 and MC3T3 cells 
for protein analysis: 
In order to study the inhibitory effect of LOXL2 on phospho-NF-κB-p65 signaling induced 
by IL-1β in both ATDC5 and MC3T3 cells, 50,000 cells were plated in each well of 12 well plates. 





washed with sterile 1X PBS and incubated with serum-free media for 24h. The next day, IL-1β (5 
ng/ml) was added to cells in serum-free media for 2 minutes, and then cells were collected in SDS-
PAGE sample buffer (0.1 mM Tris-HCl, 4% SDS, 10% glycerol, 5% β-mercaptoethanol) for 
western blot analysis. 
 
  
3.7. Using β-aminopropionitrile (BAPN) to evaluate LOXL2 enzyme activity in ATDC5 
cells: 
β-aminopropionitrile (BAPN) is LOX and LOXL specific enzyme inhibitor, which blocks 
any enzymatic fuctional role in all members of the LOX family. To evaluate the enzymatic activity 
of LOXL2 during its role in OA related factors, 50,000 ATDC5 cells plated in each well of 12 well 
plates. 1µl/ml Adv-RFP-Empty and Adv-RFP-LOXL2 transduced to the confluent cells for 24h 
and then washed with sterile 1X PBS and incubated with BAPN (400 µm) in serum-free media for 
24h. The next day, IL-1β (5 ng/ml) added to cells in serum-free media for 2 minutes and then cells 
collected in SDS-PAGE sample buffer (0.1 mM Tris-HCl, 4% SDS, 10% glycerol, 5% β-
mercaptoethanol) for Western blot analysis 
 
3.8. Western blot: 
Tissue or cell layers were extracted with SDS-PAGE sample buffer (0.1 mM Tris-HCl, 4% 
SDS, 10% glycerol, 5% β-mercaptoethanol) and boiled for 5 minutes. Protein concentrations were 
determined using Nano Orange assay kits (Molecular Probes, Eugene, OR, USA). Approximately 
30 µg of protein per experimental group was then subjected to 10% SDS-PAGE and western 





(Cell signaling, 1:1000), total NF-κB-p65 (Cell signaling, 1:1000) and β-actin (Cell signaling, 
1:1000). Anti-LOXL2 (GeneTex, 1:250) primary antibody was used too for LOXL2 detection in 
the transduced group. Membranes then incubated with anti-rabbit secondary antibody (Cell 
signaling, 1:2000) from Cell Signaling Technology for 2 hours and then Quantification was 
performed using a digital densitometry system (Versadoc; BioRad, Hercules, CA, USA) and Image 
























Antibody Species Company & catalog number Used concentration 
LOXL2 Rabbit GeneTex 105085 IHC (1:100) WB (1:250) 
Aggrecan Rabbit Abcam 36861 IHC (1:200) 
MMP13 Rabbit Abcam 39012 IHC (1:200) 
RFP Rabbit Abcam 62341 IHC (1:500) 
Phospho-NF-ĸB Rabbit Cell Signaling 3033 WB (1:1000) 
Total NF-ĸB Rabbit Cell Signaling 8242 WB (1:1000) 
β- Actin Rabbit Cell Signaling 4970 WB (1:1000) 
Anti-rabbit IgG HRP linked Rabbit Cell Signaling 7074 WB (1:2000) 





3.9. Adv-RFP-LOXL2 local injection of the Human TMJ implants in the nude mice: 
Cells from three different patients with OA were prepared in 50 µl of media and mixed 
with the Matrigel in a ratio of 1:1. The total 100 µl of chondrocyte/Matrigel suspension were 
implanted subcutaneously in the back of nude mice, three implants/mouse, and left for a week to 
grow. Weekly treatment with a local injection in the implant area of 30 µl suspension of Adv-RFP-
LOXL2 or Adv-RFP-EV (n=5/condition) for 6 weeks. Transduction was confirmed by monitoring 
the RFP by in vitro imaging systems (IVIS) every week. After that the implants were extracted, 
one implant from each mouse was processed for RNA isolation and gene array analysis. 
 
3.10.  RNA-sequencing analysis:  
RNA-sequencing library preparation was performed using a kit (Illumina, Inc) from 100 
ng of total RNA and subjected to sequencing using an Illumina 500 sequencer with 24 million 
reads per sample. The RNA Express Workflow was run twice: once using human genome hg19 
and once using mouse genome mm10. The alignment data was subjected to differential analysis 
and gene set enrichment analysis (GSEA).  
3.11. Systemic injection of Adv-RFP-LOXL2 in Cho/+ mice: 
 Twenty-four Cho/+ 4 months-old mice were divided into 2 groups (n=12 per condition) 
and received a weekly intraperitoneal injection of Adv-RFP-LOXL2 & Adv-RFP-Empty (100 µL; 
concentration 1 x 1013  infectious particles/mL) for three months. The mice were then sacrificed 
and samples collected for analysis as follows; left knee and TMJ were fixed with 4% 





of staining. Right knee and TMJ were extracted in Trizol and RNA was isolated for gene analysis 





















Figure 6. Experimental design for different groups of Cho/+ mice: In this experiment, a 
systemic injection of Adv-RFP-Empty and Adv-RFP-LOXL2 was given weekly to two groups 
for three months. After that mice were sacrificed and tissues were collected as seen in the figure 





3.12. MIA-induced OA in LOXL2 overexpression in transgenic mice:  
 To evaluate if constitutive overexpression of LOXL2 in mice protects from OA pain and 
inflammation, MIA (0.5 mg/ml) injected in the left knee (n=12/condition) of 13-month-old (aged) 
mice, comparing heterozygous LOXL2-overexpressing (LOXL2Tg/-) and wild-type littermates 
(LOXL2WT/WT) (figure 7A). Treadmill behavior has implications for the preclinical behavioral 
assessment of chronic pain and inflammation (Cobos et al., 2012).  
Treadmill analysis was performed with a standard protocol 28 days post-MIA injection. Mice were 
acclimatized to treadmill running (TSE Systems) on 3 consecutive days followed by resting for 1 
day before evaluating performance (Figure 7B). The acclimatization consisted of a 5-min rest on 
the treadmill conveyor belt followed by 5 min of running at 7.2 m/s and 5 min at 9.6 m/s. On day 
0, mice were subjected to a graded maximal running test consisting of an initial 5-min rest, after 
which the running protocol commenced at 4.8 m/min, gradually increasing by 2.4 m/min every 2 
min. At all times, the mice were running up a 5-degree incline. The researcher conducting the test 
was blinded to the genotype of the animals. Time and covered distance have been measured for 
each mouse then both right and left knee tissues were collected for immunohistochemistry studies 
(Fentz et al., 2015). 
3.13. RNA isolation: 
 Total RNA isolation was performed using Trizol (Invitrogen) protocol with isopropanol 
precipitation of the RNA pellet, washing the pellet with 70% ethanol and finally dissolving this 
pellet with RNase free water. Then RNA was purified using (Qiagen RNeasy mini kit) columns 


























Figure 7. Experimental design for LOXL2 overexpression  transgenic mice structure and 
functional analysis subjected to OA: a) WT and LOXL2 overexpressed group injected with 
subchondral 0.5 mg MIA in what volume of what buffer?? in the left knee of each mouse, right 
knee is a control. B) Time line for the experiment, MIA injection on day 0 to induce 
osteoarthritis then treadmill training three days prior to the test following TSE system. Treadmill 
test done to record time and distance differences between both groups, MIA/WT and 





3.14. RT-PCR analysis: 
Total RNA was converted to cDNA with (Applied Biosytems). Quantitative real-time PCR 
(RT-qPCR) analysis was performed using TaqMan gene expression assays from Life 
Technologies, according to a standard protocol [16]. Taq- Man® Gene Expression Assay IDs for 
mouse primers were: GAPDH (Mm99999915_g1), Sex-determining region Y-box containing gene 
9 (SOX9) (Mm00448840_m1), matrix metalloproteinase (MMP13) (Mm00439491_m1), 
Aggrecan (ACAN) (Mm00545794_m1), LOXL2 (Hs00158757_m1) LOXL2 
(Mm00804740_m1), Receptor Activator of Nuclear factor-Kappa B Ligand (RANKL) 
(Mm00441906_m1) and a disintegrin and metalloproteinase with thrombospondin motifs 5 
(ADAMTS5) (Mm00478620_m1) (Table 2). 
 
3.15. Fixation and decalcification of mouse tissues: 
Tissue samples were fixed in 4% formaldehyde for 24h then placed in cassettes for 
decalcification with 10% (EDTA) solution for 14 days and stored after that in 1X PBS and glycerol 
for future sectioning. 
 
3.16. Safranin O/fast green staining for proteoglycan analysis: 
In order to detect proteoglycan expression in the cartilage area, Safranin O staining was 
performed forall TMJ and knee tissues. Paraffin sections were deparaffinized with Xylene for 5 
minutes two times then hydrated with alcohol (100%, 80%, then 50%) to distilled water. The 





followed by a wash in tap water for 1 minute. After that slides were incubated with fast green 
solution for 3 minutes and then washed with 1% acetic acid solution for 15 seconds. Immediately 
followed by incubation with 0.1% Safranin O solution for 5 minutes, then dehydrated with absolute 
alcohol for minute (three changes), and xylene for 2 minutes (two changes), and covered with 












RT-PCR primer name Assay number 
GAPDH Mm99999915_g1 





RANKL (TNSF11) Mm00441906_m1 





3.17. Immunohistochemistry (IHC) for mouse tissues:  
The isolated tissues were placed in a labeled holder then dehydrated for 14.5 hours in 
dehydration machine (sequence of dehydration solution used from alcohol to xylene to melt 
paraffin). After that tissues were embedded using melted paraffin and cooled at room temperature 
to solidify to form blocks. Blocks were sectioned at 4 microns thickness and tissues floated onto 
the slides in a 43℃ hot water bath. Paraffin was melted off the slides in the oven and the slides 
were processed in the de-paraffinizing machine (xylene and dehydration graded alcohol from 
100% to 75% to pure water). The slides then were incubated with 0.1% Triton X-100 (cat#. T8200) 
for 15 min at room temperature and then washed in PBS three times, 5 min each time. The slides 
were incubated with protein blocking reagent (Servicebio, G5001) for 20 minutes at room 
temperature and then with rabbit primary antibodies; anti-MMP13 (abcam 39012, 1:200), anti-
LOXL2 (GeneTex 105085, 1:100), anti-RFP (abcam 62341, 1:500) and anti-Aggrecan (abcam 
36861, 1:200) overnight at 4℃. Following the primary antibody incubation, the slides were washed 
with 0.05% TBST (0.05 ml Tween 20/100 ml TBS solution) 5 times, 5 min each time. After that, 
the slides were incubated with rabbit IgG  secondary antibody for 50 minutes at room temperature 
and washed after that in saline solution three times, 5 min each time. The slides were stained with 
DAB and hematoxylin, then covered with a water-soluble resin. Whole field was subjected to 










3.18. Using animal experiments:  
All mouse experiments were performed with guidance, regulations, and approval of Boston 
University Institutional Animal Care and Use Committee (IACUC; approval number AN-15387). 
The preclinical animal study conformed to the ARRIVE guidelines. 
 
3.19. Data analysis:  
Data analyses were performed using t-test and one-way analysis of variance (ANOVA) 
with Bonferroni post-hoc analysis or Student’s t test (Graph Pad Prism 5 software). All 
experiments were performed three times each using ATDC5 and MC3T3 cells. Each data point is 
























The goal of the study was to evaluate the protective function of LOXL2 in TMJ and knee 
joint OA. We performed a series of studies to evaluate the effect of LOXL2 in IL-1β in ATDC5 
and MC3T3 cells, human cartilage implants in nude mice, Cho+/- mouse model TMJ and knee 
joint,  and finally validated structure and function in LOXL2 overexpression mice. 
 
 
4.1. LOXL2 inhibits phospho-NF-κB/p65 signaling pathway induced by IL-1β in 
ATDC5 cells: 
Since phospho- NF-κB/p65 signaling pathway plays a role in the inflammatory process of 
OA, we validated the inhibitory effects of LOXL2 on this pathway induced by IL-1β in ATDC5 
cells. 50,000 cells were plated in each well of 12 well plates. 1µl/ml Adv-RFP-Empty and Adv-
RFP-LOXL2 was added to the confluent cells for 24h and then washed with sterile 1X PBS and 
incubated with serum-free media for 24h. The next day, IL-1β (5 ng/ml) was added to cells in 
serum-free media for 2 minutes, and then cells were collected in SDS-PAGE sample buffer (0.1 
mM Tris-HCl, 4% SDS, 10% glycerol, 5% β-mercaptoethanol) for western blot analysis. We found 
that LOXL2 inhibited IL-1β-induced phospho-NF-κB/p65 levels significantly compared to the 
control group, as shown in the western blot analys (Figure 8B).  
 
 4.2. LOXL2 Attenuation of IL-1β induced adverse effects in ATDC5 cells: 
In order to evaluate a LOXL2 anti-catabolic role on IL-1β adverse effect of OA related 
genes such as aggrecan (important cartilage proteoglycan), SOX9 (important for chondrocyte 





cells were treated with IL-1β and transduced with Adv-RFP-LOXL2 and Adv-RFP-Empty, and 
RT-PCR was done.  IL-1β treatment was shown to downregulate the levels of  LOXL2 compared 
to the control group. First, LOXL2 evaluation for all groups was done to confirm LOXL2 
expression (Figure 9B). The inhibition effect of ADAMTS5 (Figure 12) and MMP13 (Figure 13) 
was significant on day 3 but not on day 1 (Figure 12C and 13C). Other anabolic related genes 
aggrecan (major proteoglycan in cartilage) and SOX9 (important for chondrocyte differentiation) 
levels decreased when IL-1β was added (Figure 10 and 11). LOXL2 transduction rescued these 
expression levels back to normal levels on day 3 for aggrecan (Figure 10C) and on day1 for SOX9 
(Figure 11B). In conclusion, this confirmed the anti-catabolic effect of LOXL2 on IL-1β adverse 






























Figure 8. LOXL2 inhibits IL-1β-induced phospho-NF-ĸB in ATDC5 cells: a) Design of the 
experiment. b) Western blot analysis for Adv-RFP-LOXL2 inhibition effect of phospho-NF-ĸB 
signaling pathway induced by IL-1β in ATDC5 cells. c) Quantification of relative expression of 
phospho-NF-ĸB to β-actin normalized to the Empty group. Data analyzed using one way 












Figure 9. LOXL2 mRNA expression in ATDC5 cells after transduction with Adv-RFP-
LOXL2: a) ATDC5 cells plated in 6-well plates and transduced with Adv-LOXL2 and Adv-
Empty for 24h. On the second day cells were washed with 1X PBS and treated with IL-1β in 
chondrocyte differentiation media (readymade from Cell Application). Cells were then collected 
on day1 and day 3 with Trizol and total RNA isolation for gene analysis. b) RT-PCR to assess 
LOXL2 expression in all groups on c) day1 and d) day 3 indicating the presence of LOXL2 at 







Figure 10. LOXL2 promotes aggrecan mRNA expression and protects from IL-1β adverse 
effects in ATDC5 cells: a) RT-PCR for aggrecan expression on both b) day1 and c) day 3 in all 
groups. Aggrecan expression is significantly higher in the LOXL2 transduced group on day 3. 
IL-1β inhibited aggrecan levels but with LOXL2 transduction restored this level to almost the 






Figure 11. LOXL2 promotes SOX9 mRNA expression and protects from IL-1β adverse 
effects: a) RT-PCR for SOX9 expression on both b) day1 and c) day 3 in all groups. SOX9 
expression was significantly higher in the LOXL2 transduced group on both day 1 and day 3. 
IL-1β inhibited SOX9 levels but LOXL2 transduction restored this level to almost the normal 







Figure 12. LOXL2 attenuates ADAMTS5 mRNA expression which induced by by IL-1β: 
a) RT-PCR for ADAMTS5 expression on both b) day1 and c) day3 in all groups. IL-1β 
increases ADAMTS5 level but LOXL2 transduction restored this level to almost the normal 






Figure 13. LOXL2 attenuates MMP13 mRNA expression which induced  by IL-1β:     
a) RT-PCR for MMP13 expression on both b) day1 and c) day3 in all groups. IL-1β 
increases MMP13 level but LOXL2 transduction restored this level to almost the normal 





4.3. LOXL2 inhibits phospho-NF-κB/p65 signaling pathway induced by IL-1β in MC3T3 
cells: 
We then investigated the inhibitory effects of LOXL2 on the phospho-NF-κB signaling 
pathway in MC3T3 cells. 50,000 cells were plated in each well of 12 well plates. 1µl/ml Adv-
RFP-Empty and Adv-RFP-LOXL2 was added to the confluent cells for 24h and then washed with 
sterile 1X PBS and incubated with serum-free media for 24h. The next day, IL-1β (5 ng/ml) was 
added to cells in serum-free media for 2 minutes, and then cells were collected in SDS-PAGE 
sample buffer (0.1 mM Tris-HCl, 4% SDS, 10% glycerol, 5% β-mercaptoethanol) for western 
blot analysis. We found that LOXL2 inhibits IL-1β-induced phospho-NF-κB/p65 levels 
significantly compared to the control group, as shown in the western blot analysis (Figure 14).  
 
4.4. LOXL2 attenuation of IL-1β induced adverse effects in MC3T3 cells: 
In order to study a LOXL2 anti-catabolic role on IL-1β adverse effects of OA related 
genes such as MMP13 and RANKL, MC3T3 cells were treated with IL-1β and transduced with 
Adv-RFP-LOXL2 and Adv-RFP-Empty, and collected in 24/48h for RT-PCR analysis.  Firstly, 
we assessed LOXL2 levels in all groups to confirm its presence (Figure 15). Then we found that 
LOXL2 protects from the adverse effects induced by IL-1β significantly in the 48h group and 
restored the expression level of both MMP13 and RANKL to almost the normal levels (Figure 
16C and 17C). This confirmed the anti-catabolic effect of LOXL2 on osteoblasts in addition to 








Figure 14. LOXL2 inhibits IL-1β-induced phospho-NF-ĸB in MC3T3 cells: a) Design of the 
experiment. b) Western blot analysis for Adv-RFP-LOXL2 inhibition of phospho-NF-ĸB 
signaling pathway induced by IL-1β in MC3T3 cells. c) Quantification of relative expression of 
phospho-NF-ĸB to β-actin normalized to the Empty group. Data analyzed using one way 













Figure 15. LOXL2 mRNA expression in MC3T3 cells after transduction with Adv-RFP-
LOXL2: a) MC3T3 cells were plated in 6 well plates and transfected with Adv-LOXL2 and 
Adv-Empty for 24h. On the second day cells were washed with 1X PBS and treated with IL-1β  
in osteoblast differentiation medium (α-MEM supplemented with 10 nM dexamethasone, 25 µg 
ascorbic acid and 10 mM β-glycerophosphate). Cells then collected after 24h and 48h with 
Trizol, and total RNA was isolated for gene analysis. b) RT-PCR to assess LOXL2 expression in 
all groups at c) 24h and d) 48h indicated the presence of LOXL2 at both time points in the 







Figure 16. LOXL2 attenuates MMP13 induced by IL-1β: a) RT-PCR for MMP13 expression 
at both b) 24h and c) 48h in all groups. IL-1β increased MMP13 levels.LOXL2 restored this 







Figure 17. LOXL2 attenuates RANKL induced by IL-1β: a) RT-PCR for RANKL expression 
at b) 24h and c) 48h. IL-1β increased RANKL levels, while LOXL2 transduction rescued levels 





4.5. LOXL2 +/- BAPN inhibits phospho-NF-κB/p65 signaling pathway induced by IL-1β 
in ATDC5 cells: 
   In order study a role for the enzymatic activity of LOXL2 on its anabolic effects in bone 
and cartilage related cells, BAPN (400 µm) was added with the LOXL2 to assess the inhibitory 
effect on phospho-NF-κB/p65 signaling pathways induced by IL-1β. We found that LOXL2 
inhibitory effect is independent of the enzyme activity, as shown in our data that  LOXL2 in the 








Figure 18. LOXL2 inhibits IL-1β-induced phospho-NF-ĸB  in presence of LOXL2 enzyme 
activitiy inhibitor BAPN in ATDC5 cells: a) Western blot analysis for BAPN effects on 
LOXL2 inhibition of phospho-NF-ĸB signaling induced by IL-1β in ATDC5 cells. b) 
Quantification of relative expression of phospho-NF-ĸB to β-actin normalized to the Empty 





4.6. Gene analysis of TMJ cartilage implants in nude mice: 
RNA-sequencing library preparation was performed using a kit (Illumina, Inc) from 100 
ng of total RNA and subjected to sequencing using an Illumina 500 sequencer with 24 million 
reads per sample. The RNA Express Workflow was run twice: once using human genome hg19 
and once using mouse genome mm10. The alignment data was subjected to differential analysis 
and gene set enrichment analysis (GSEA). Analysis revealed that TMJ samples treated with Adv-
RFP-LOXL2 have higher expression of anabolic cartilage-related genes such as aggrecan and 
SOX9 and lower expression of catabolic genes such as NFKB1 and related fibrotic genes as MYH1 
and TTN. This analysis indicates that local injection of TMJ-OA implant in nude mice with 















Figure 19. LOXL2 promotes anabolic genes expression in TMJ-OA implants in nude mice: 
a) In vitro imaging systems (IVIS) imaging of human articular chondrocytes (HAC)/Matrigel 
implants in nude mice after local injection every week for 6 weeks with Adv-RFP-Empty and 
Adv-RFP-LOXL2. Weekly local injection with Ad-RFP-LOXL2 or Ad-RFP-EV, harvested after 
6 weeks, and analyzed by RNA-seq analysis. b) Global expression of the genes by RNAseq 
analysis for human TMJ-OA implants in the nude mice for  the LOXL2 treated group and the 





4.7. Gene expression analysis for TMJ and knee tissues in Cho/+  mice:  
RT-PCR for of ACAN, LOXL2, SOX9 and MMP13 genes of TMJ and knee tissues for 
the LOXL2 and the empty treated groups (G1 and G2) showed that LOXL2 expression was 
increased in the LOXL2 transduced group which indicates successful delivery of the Adv-RFP-
LOXL2 to the targeted area (Figure 20A and 24A). However, MMP13 expression levels did not 
change significantly in both groups (Figure 20D and 24D), but aggrecan (Figure 20B and 24B) 
and SOX9 (Figure 20C and 24C) levels were found to be increased in the LOXL2 transduced 
group.  This confirmed the anti-catabolic effect of LOXL2 in TMJ and knee joints of Cho/+ OA 
model.  
 
4.8. Proteoglycan expression in Cho/+  mice:  
In order to assess proteoglygan expression in the articular cartilage area, Safranin O/Fast 
green staining of the different groups in Cho/+ mouse model was done and revealed that systemic 
injection of Adv-RFP-LOXL2 promotes its anticatabolic effect on cartilage of both TMJ and knee 
by rescuing proteoglycan expression from adverse effect of OA. Proteoglycan expression in the 
cartilage area was found to be significantly higher in the LOXL2 group compared to the Empty 
group in both TMJ (Figure 25) and knee joints (Figure 21). This indicates that LOXL2 restores an 
important cartilage related feature from being lost in OA. 
 
4.9. IHC analysis for TMJ and knee tissues in Cho/+  mice:  
In order to evaluate the expression differences of some cartilage related genes in TMJ and 





Aggrecan and anti-MMP13. RFP was found to be present in both groups which indicates that 
systemic injection of Adv-RFP-Empty and Adv-RFP-LOXL2 was delivered effectively in the 
cartilage area of both tissues (Figure 22A and 26A). In the LOXL2 group, LOXL2 expression was 
higher than the empty group and confirmed the presence of LOXL2 in that group of both TMJ and 
knee samples (Figure 22B and 26B). Also aggrecan expression was found to be significantly higher 
in the LOXL2 group as seen in (Figure 23A and 27A); however, MMP13 expression was 
significantly lower in LOXL2 group as seen in (Figure 23B and 27B). This indicated that LOXL2 









Figure 20.  Systemic LOXL2 protective effects on different mRNA genes expression in knee 
tissues: RT-PCR was done for the knee tissues to evaluate the expression of different genes 
expression differences between the groups. a) LOXL2 level is significantly higher in the LOXL2 
transduced group which indicates that the systemic injection of LOXL2 successfully increased its 
expression in this area. b) aggrecan and c) SOX9 expression are also higher in the LOXL2 
transduced group indicating the anabolic effect for these important cartilage related genes. d) 
MMP13 level didn’t change significantly in both groups. Data analyzed using t-test (***p< 0.001). 







Figure 21. Proteoglycan expression with safranin O/Fast green staining in the articular 
cartilage of knee tissues: a) Knee tissues were stained to assess the proteoglycan expression 
in the articular cartilage area. This expression is obviously higher in the LOXL2 group 
compared to the control. b) Quantification of the stained area in both groups normalized to 








Figure 22.  The protective effect of LOXL2 in articular cartilage of knee tissues 
deomonstreated by immunohistochemistry:  a) RFP expression in both group indicates 
Adv-RFP injection effect in the cartilage area, b) in addition LOXL2 expression is higher in 
the LOXL2 transduced group compared to the Empty and confirms LOXL2 expression in 















Figure 23.  The protective effect of LOXL2 in articular cartilage of knee tissues using 
immunohistochemistry: a) LOXL2 promotes aggreacan expression in the LOXL2 transduced 
group compared to the Empty group, b) on the other hand LOXL2 attenuates MMP13 







Figure 24. The protective effect of LOXL2 on different mRNA genes expression in TMJ 
tissues: RT-PCR was done for the TMJ tissues to evaluate the expression of different gene 
expression differences between the groups. a) LOXL2 level is significantly higher in the LOXL2 
transduced group, which indicates that the systemic injection of LOXL2 successfully increased 
its expression in this area. b) aggrecan and c) SOX9 expression are also higher in the LOXL2 
tranduced groups indicating the anabolic effect for these important cartilage related genes. d) 
MMP13 level didn’t change significantly in both groups. Data analyzed using t-test (***p< 







Figure 25. Proteoglycan expression with safranin O/Fast green staining in the condylar 
cartilage of TMJ tissues: a) TMJ tissues of both groups were stained to assess the proteoglycan 
expression in the articular cartilage area. This expression was obviously higher in the LOXL2 
group compared to the control. b) Quantification of the stained areas in both groups normalized 







Figure 26. The protective effect of LOXL2 in condylar cartilage of  TMJ tissues using 
immunohistochemistry:  a) RFP expression in both group indicates Adv-RFP injection 
effect in the cartilage area, b) LOXL2 expression is higher in the LOXL2 treated group 
compared to the control group and confirms LOXL2 expression in the area. Data analyzed 







Figure 27. The protective effect of LOXL2 in condylar cartilage of TMJ tissues using 
immunohistochemistry: a) LOXL2 promotes Aggreacan expression in LOXL2 treated group 
compared to the Empty one, b) on the other hand LOXL2 attenuates MMP13 expression 





4.10. Protection effect of knee joint function in MIA/LOXL2 overexpression transgenic 
mice: 
Treadmill analysis was performed with a standard protocol 28 days post-MIA injection. 
Mice were acclimatized to treadmill running (TSE Systems) on 3 consecutive days followed by 
resting for 1 day before evaluating performance. Time and covered distance have been measured 
for each mouse separately. LOXL2-overexpressing mice spent more time and covered more 
traveled distance than MIA/WT littermates (Figure 28). Allodynia pricking test revealed that 
LOXL2-overexpression group was less sensitive to the fillaments compared to MIA group (Figure 
29). Thus, LOXL2 could protect against OA-like exercise response and pain sensitivity due to 
injection of MIA.  
 
4.11.  Proteoglycan expression is higher in MIA/LOXL2 overexpression transgenic mice: 
In order to assess proteoglygan expression in the articular cartilage area, Safranin O/Fast 
green staining of the different groups is done and revealed that proteoglycan expression in the 
articular cartilage was reduced in the MIA/WT group compared to WT.  On the other hand; 
LOXL2 promoted a protective effect by inhibiting the adverse effect of MIA related OA and kept 









4.12.  Higher aggrecan and less MMP13 expression in MIA/LOXL2 overexpression 
transgenic mice: 
Immunohistochemistry is done for all groups to evaluate the expression of different 
cartilage-related genes. LOXL2 was found to be increased significantly in both the LOXL2 and 
the MIA/LOXL2 group compared to the controls which confirm the presence of higher levels of 
LOXL2 in the targeted area (Figure 31). In the MIA group, aggrecan expression decreased 
significantly compared to WT group, but this expression was rescued and stayed at comparable 
level asWT in the MIA/LOXL2 group (figure32). On the other hand, MMP13 increased with 
MIA related OA and LOXL2 over-expression this level did not decrease (Figure 33). This 
indicates that LOXL2 induces an anabolic effect by protecting cartilage-specific proteins from 










Figure 28. Treadmill test (TSE system) time and distance differences between MIA 
injected WT and LOXL2 group: a) Treadmill running time differences in minutes between 
MIA/WT and MIA/LOXL2 groups. b) Distance covered differences between both groups. Data 






Figure 29. Allodynia pricking test for the MIA injected WT and LOXL2 group: Pain 
sensitivity test was done using a Von Frey Hair monofilaments kit. Each color of the kit 
represents a filament size with different applyied force. Pain assessments are done by pricking 
the knee area of the target mouse with different filament and assessing the paw withdrawal of the 
mice, so mice in pain will be more sensitive than others. Data analyzed using t-test (**p< 0.001). 







Figure 30. Proteoglycan expression with safranin O/Fast green staining in the articular 
cartilage area for all groups: a) Tissues were stained to assess the proteoglycan expression in 
the articular cartilage area. MIA induced group showed significantly lower proteoglycan 
expression compared to wild type. In the MIA/LOXL2 overexpressed group, LOXL2 protects 
proteoglycan expression from MIA adverse effects and kept it at almost at the normal level. b) 
Quantification of the stained area in all groups normalized to WT. Data analyzed using one way 






Figure 31. LOXL2 expression in the articular cartilage area in all groups using 
immunohistochemistry analysis: a) Tissues of all groups stained by IHC to evaluate the 
LOXL2 expression in the LOXL2 and MIA/LOXL2 groups. LOXL2 was expresses at higher 
levels in both LOXL2 groups compared to both WT and MIA  injected groups. b) Quantification 
of the brown stained area in the articular cartilage normalized to WT group. Data analyzed using 








Figure 32. Aggrecan expression in the articular cartilage area in all groups using 
immunohistochemistry analysis: a) Tissues of all groups stained with IHC to assess for 
aggrecan expression differences. In the MIA group, aggrecan expression decreased significantly 
compared to WT, but in MIA/LOXL2 this level was  protected and remained near the normal 
limit. b) Quantification of brown stained area in the articular cartilage normalized to WT. Data 







Figure 33. MMP13 expression in the articular cartilage area in all groups using 
immunohistochemistry analysis: a) Tissues of all groups stained by IHC to assess the MMP13 
expression differences between them. In MIA group, MMP13 expression significantly increased 
compared to WT, but in the MIA/LOXL2 group this level was  protected and remained near the 
normal limit. b) Quantification of brown stained area in the articular cartilage normalized to 







Gene therapy approaches using adenovirus and lentivirus by direct intra-articular joint 
and intraperitoneal injections have been used extensively in preclinical and clinical studies 
(Evans et al., 2018). Adenovirus-mediated administration of bFGF, IL-1Ra, or IGF-1 was 
effective in a rat OA model (Chen et al., 2010). The TMJ differs structurally from other joints 
(Hinton, 2014): it contains fibrocartilage as well as mandibular condylar cartilage (MCC). The 
MCC distinguishes the TMJ from the articular cartilage of the limbs and cartilage in the cranial 
base. Differences in the MCC include rapid chondrocyte hypertrophy with an overlapping 
expression of collagen (COL) 1, 2, and 10 (Shibata et al., 1997); the absence of growth factors 
GDF-5 and GDF-6 (Purcell et al., 2009); specific osteopontin and bone sialoprotein expression 
(Gu et al., 2008); and unique responses to gene inactivation (Yasuda et al., 2010). Furthermore, 
TMJ cartilage expresses specific proteins that differ from those found in a knee or hip joint 
cartilage; and is a more complex tissue.  
While we seek to understand how LOXL2 exerts effects on pro-inflammatory and anabolic factors 
in the pathogenesis of OA, the overarching goal of these studies is to evaluate if LOXL2 could be 
used for translational research and future clinical applications in OA treatment. The role of LOXL2 
in vivo in cartilage development, maintenance, and protection in TMJ OA is not known.  This 
study offers several conceptual innovations in OA. Indeed, it is the first to propose a role for 
LOXL2 in OA pathophysiology. We are especially interested in how LOXL2 affects the IL-1β 






LOXL2 could induce a chondroprotective response through inhibition of inflammation- or stress-
induced signaling pathways or through an unknown epigenetic mechanism, which will be 
evaluated through a series of in vitro and in vivo studies. In chondrocytes, IL-1β  activates the 
canonical NF-κB pathway, which is dependent upon IKKα, leading to increased gene expression 
of MMPs, ADAMTSs, inflammatory mediators (COX2, NO, PGE2), chemokines (IL-8), and 
cytokines (IL-1β, TNF-α, IL-6) that are involved in cartilage destruction. In contrast, the non-
canonical NF-κB activating kinase, IKKα, is a novel effector of human and murine chondrocyte 
ECM homeostasis and differentiation toward hypertrophy (Olivotto et al., 2013). Due to persistent 
NF-κB activity, some chondrocytes shift to a hypertrophic phenotype.   
Cho/+ mice lead to progressive TMJ and knee OA starting at the age of 3 months, with increasing 
severity up to the age of 15 months (Salazar et al., 2014),  (Xu et al., 2003),  (Xu et al., 2010), (Xu 
et al., 2005). The progressive changes in the cartilage of Cho/+ mice are: 1) at age 6 months, loss 
of proteoglycan staining at the superficial zones; 2) at 9 months, the region of 
deficient proteoglycan staining extended from the superficial to the deep layers;  and 3) by 15 
months of age, typical OA-like joints, including loss of cartilage, misshaped meniscus, and 
inflammation in the synovial tissues, compared to wild-type (WT) littermates (Xu et al., 
2003). At 3 and 6 months, respectively, the ECM-degrading proteins MMP-3 and MMP-13 are 
increased in TMJ and knee joints from Cho/+ mice compared to WT littermates. MMP13 is 
implicated in OA pathogenesis, as is RANKL (TNFSF11) (Martinez-Calatrava et al., 2012), which 
is an NF- κB ligand that promotes bone loss. Thus, the Cho/+ model enabled us to evaluate the 






Whether defective LOXL2 function leads to OA, is not known.  In OA, collagen crosslinking is 
reduced, making the ECM more susceptible to degradation. ADAMTS 4/5 and MMP13 are the 
major proteinases that degrade proteoglycans and collagens, respectively, leading to pathological 
changes in OA cartilage. IL-1β promotes ADAMT5 and MMP13 in OA. LOXL2-induced 
collagen cross-linking enhances the tensile strength of articular cartilage and resistance to 
collagen proteolysis (Makris et al., 2014).  LOXL2 has roles in collagen crosslinking and 
maturation. Mutation of collagen XI (Cho/+) (10) or Col2a1 (Ala-Kokko et al., 1990) in mice 
leads to disruption of cartilage matrix, increasing susceptibility to degradation (Vos et al., 2013). 
Structural modifications in collagen could alter the substrate specificity of LOXL2 function, which 
will be evaluated by genetic and epigenetic studies.   
LOXL2 is not an oncogene, but a naturally acting enzyme in ECM. ECM remodeling is crucial for 
the development of normal organs, whereas dysregulation of ECM depends on increased LOXL2 
expression and contributes to several pathological conditions, such as fibrosis and invasive cancer 
(Akiri et al., 2003), (Barker et al., 2012), (Bonnans et al., 2014). Moreover, studies have shown 
that extracellular and nuclear LOXL2 have different functions (Moon et al., 2013). We showed 
that recombinant LOXL2 or Adv-LOXL2 does not induce proliferation but only induces 
differentiation in osteoarthritic chondrocytes (Alshenibr et al., 2017). LOXL2 protein has cysteine-
rich scavenger receptor domains, enzymatic domains and other functional domains, which could 
have a specific role in OA, and this study suggests that specific domains should be the focus for 





FGF18 and BMP7 are in phase 1 clinical trials for OA. FGF18 has also been shown to promote 
colorectal cancer (Sonvilla et al., 2008). BMP7 increases breast cancer proliferation, migration, 
and invasion (Alarmo et al., 2009). Similar to FGF18 and BMP7, LOXL2 is not an oncogene. 
Taken together, intermittent administration of LOXL2 and nuclear LOXL2 function in OA shows 
that LOXL2 could be used as a regenerative cartilage therapy in OA.  
LOXL2 regulates aggrecan expression in our LOXL2 overexpressed Cho/+ mouse model. The 
LOXL2-induced proteoglycan network in cartilage is critical for maintaining normal joint 
homeostasis. Whether defective LOXL2 function leads to OA has not been evaluated. Altered 
ECM-related proteins have the propensity to develop OA. For example, in OA joints, collagen 
crosslinking is defective, and collagen is more susceptible to degradation (Vos et al., 2014), and a 
single point mutation in Col11a1, as seen in Cho/+ mice (Xu et al., 2003), or Col2a1 (Ala-Kokko 
et al., 1990) leads to OA. Intracellular roles of LOXL2 in molecular signaling and epigenetic 
modification may also affect the development of OA. 
Further adenovirus gene therapy-based applications are in clinical development and approved for 
OA (Evans et al., 2018). Although injection of LOXL2 increased the expression of aggrecan, 
safranin-O staining and other anabolic effects were characterized to provide mechanistic clues. 
However, the detailed understanding of molecular mechanisms by which LOXL2 exerts its 
anabolic effects will be investigated in the future.   
Taken together, since the goal here was to evaluate if an injection of adenovirus-LOXL2 could 
induce an anabolic and protective response in the TMJ and knee joints, LOXL2 was assessed in 





OA-associated changes with age; this model allowed us to determine that LOXL2 has a beneficial 
effect in blocking the progression of OA. The second model is the TMJ-OA implants in the back 
of nude mice which received local injection of Adv-LOXL2. Using a combination of various tools 
and models, we showed that LOXL2 delivered by adenovirus in vivo produces both 
chondroprotective and anabolic effects in TMJ and knee joints. These data have therapeutic 
implications as to the potential efficacy of mediators of LOXL2 in treating OA affected joints. 
 
In conclusion 
• LOXL2 inhibits phospho-NF-ĸB signalling pathways induced by IL-1β in ATDC5 and 
MC3T3 cells and have a strong potential to inhibit the adverse effects induced by OA-
related factor IL-1β.  
• LOXL2 transduction of human implanted cartilage induced anabolic responses and 
maintained the cartilage phenotype by increasing expression of cartilage-specific matrix 
genes such as SOX9 and aggrecan. 
• LOXL2 overexpression in transgenic mice protects MIA-induced OA joints and protects 
the joint from adverse effects related to OA. 
• Systemic injection of LOXL2 in Cho+/- model induces protective effects of OA affected 
TMJ and knee joints.  
• The study has evaluated if attenuating IL-1β signaling inhibits knee joint-OA, which could 
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